Opinion|Videos|September 15, 2023
Patient Scenario: A 65-Year-Old Man with HER2+ mCRC
Daniel Walden, MD, presents the scenario of a 65-year-old man diagnosed with HER2+ metastatic colorectal cancer to the expert panel for discussion.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.
The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5